Orion (ORNBV) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales rose 13.4% to €328.2 million, with operating profit up 41.5% to €65.8 million, driven by Nubeqa and Animal Health.

• H1 2024 net sales increased 12.2% to €636.7 million and operating profit grew 19.5% to €121.8 million, with all business units contributing, led by Nubeqa, Easyhaler, and Animal Health.

• Operating margin improved from 16.1% to 20.1% in Q2, reflecting positive product mix and margin development.

• Growth achieved despite planned R&D expense increases.

• Cash flow improved due to pension fund transfer and milestone payments.

Financial highlights

• Q2 2024 net sales: €328.2M (+13.4% YoY); operating profit: €65.8M (+41.5% YoY); margin: 20.1%.

• H1 2024 net sales: €636.7M (+12.2% YoY); operating profit: €121.8M (+19.5% YoY); margin: 19.1%.

• Nubeqa sales in H1: €121.1M (+45.9%); Innovative Medicines sales: €137.5M (+46.0%).

• Easyhaler sales grew 19% to €81.2M; Animal Health sales rose 22.8% to €61.8M.

• Cash flow from operating activities per share: €0.98 in H1 2024, up from €0.27, reflecting pension fund transfer and milestone recognition.

Outlook and guidance

• 2024 outlook upgraded: net sales expected at €1.44–1.48 billion, operating profit at €350–380 million.

• Upgrade driven by €60 million balance sheet item release and better-than-expected H1 performance.

• No major headwinds anticipated for H2; R&D costs to grow but within outlook.